Detailing Characteristics of Fibrostenotic Crohn’s Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy

8th Annual Antifibrotic Drug Development (AFDD) Summit
November 21, 2024

Colonic Bioactivation and Potent TNFa Inhibition of PALI-2108 in Human Clinical Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis

ACG’s 2024 Annual Scientific Meeting
October 25, 2024

Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment

Digestive Disease Week (DDW) 2024
May 21, 2024

Advancing PALI-2108: Discovery to Strategic Positioning

IBD Innovate: Product Development for Crohn’s & Colitis™
April 9, 2024

Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment

Crohn’s & Colitis Congress 2024
January 26, 2024